Just when it looked like the year would end without another mega-merger, Illumina has swooped in to acquire its rival, Pacific Biosciences (PacBio), for $1.2 billion.

Each year in the United States, at least two million people become infected with antibiotic-resistant infections--so-called super bugs.

Anyone who has had BRCA1 or BRCA2 testing can log onto My Gene Counsel to learn about their gene and variant, and what they can do about the finding.

Ellen Matloff, president & CEO of digital health company My Gene Counsel, says she was adamantly opposed to DTC testing just six years ago.

Danaher today reported a 7 percent year-over-year increase in its third quarter revenues with its diagnostic revenues up 3 percent.

Agena Biosciences and DaRui Biotechnology announced today that Agena's MassArray system has been cleared by the China Food and Drug Administration.

An estimated 100 million-plus people, roughly one-third of the U.S. population, will have had their DNA analyzed using an at-home genetic test kit by 2021.

When it comes to in vitro diagnostic (IVD) technologies, medical device and diagnostic companies have been chomping at the bit to produce the next big innovation.

CARLSBAD, MA, UNITED STATES - Oct 17, 2018 - Marking a milestone in bringing its Oncomine Dx Target Test to Europe

Bacterial or viral infection, that is the question. Haifa-Israel based MeMed Diagnostics is developing a point-of-care platform and immune-based test that will one day be able to provide answers.

Patients living with autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), or multiple sclerosis must see their health practitioners frequently to check the progression of their conditions and their responses to therapies.

BGI has analyzed the world’s largest set of genome data from pregnant women, a total of 141,431 expectant mothers from across China.

After setting its sights on a $100 million IPO, CAR-T player Allogene Therapeutics has nearly tripled that, pricing the deal at the high end of the range and raising $288 million.

It's hard to believe it's been a full year since Abbott closed its acquisition of Alere, considering what a contentious deal it was and how hard Abbott fought last year to get out of it.

Thermo Fisher Scientific said recently that its third quarter revenues grew 16 percent, driven by growth across its four business segments.